Roivant Sciences Ltd.·4

Jul 2, 7:03 PM ET

Fitzgerald Meghan 4

Research Summary

AI-generated summary

Updated

Roivant (ROIV) Director Meghan Fitzgerald Exercises Options, Sells 10,000 Shares

What Happened Meghan Fitzgerald, a director of Roivant Sciences Ltd. (ROIV), exercised stock options and sold shares on June 30, 2026. The filing shows she exercised 10,000 options at $8.80 per share (cost $88,000) and disposed of 10,000 shares in an open-market sale at $34.90 per share (gross proceeds $349,000). The report also records a derivative conversion/disposition of 10,000 shares at $0.00. A footnote (F1) notes these were awards of fully vested stock options.

Key Details

  • Transaction date: 2026-06-30.
  • Exercise: 10,000 shares at $8.80 each — $88,000 paid (Form 4 "M" code).
  • Sale: 10,000 shares at $34.90 each — $349,000 gross proceeds (Form 4 "S" code).
  • Derivative conversion/disposition: 10,000 shares at $0.00 recorded as disposed (Form 4 "M" code).
  • Footnote F1: Award of stock options that is fully vested.
  • Filing date: 2026-07-02 (appears timely based on the Form 4 filing window).
  • Shares owned after transaction: Not specified in the provided summary of the filing.

Context Because the exercised amount (10,000) matches the shares sold (10,000) on the same date, this effectively functions like a cashless exercise and sale — the exercise generated shares that were immediately sold. The $0.00 derivative disposition entry likely reflects a conversion/settlement event tied to the option award; consult the full Form 4 for the issuer's precise mechanics and any additional notes. As always, insider sales can be routine (tax or liquidity needs) and do not by themselves indicate company performance.